Arvanitis D, Malliri A, Antoniou D, Linardopoulos S, Field J K, Spandidos D A
Department of Pathology, Children's Hospital Aghia Sophia, Athens, Greece.
In Vivo. 1991 Jul-Aug;5(4):317-21.
We have employed an immunohistochemical analysis to study the ras p21 oncoprotein in a total of 41 brain tumors and 1 reactive gliosis. The tumors included 33 astrocytomas, 1 oligodendroglioma, 2 ependymomas, 1 neurilemmoma, 1 malignant meningioma, 1 neuroblastoma and 2 medulloblastomas. Our results indicate that elevated ras p21 expression is a common feature in a range of brain tumors. In particular, elevated ras p21 expression has been found in 18 out of 24 high grade astrocytomas (malignant astrocytomas and glioblastomas multiforme) compared to 3 out of 9 low grade (well differentiated astrocytomas) (P less than 0.05). These results suggest that ras p21 expression may be an important molecular marker of the malignant astrocytomas and glioblastomas multiforme.
我们采用免疫组织化学分析方法,对总共41例脑肿瘤和1例反应性胶质增生进行了ras p21癌蛋白研究。这些肿瘤包括33例星形细胞瘤、1例少突胶质细胞瘤、2例室管膜瘤、1例神经鞘瘤、1例恶性脑膜瘤、1例神经母细胞瘤和2例髓母细胞瘤。我们的结果表明,ras p21表达升高是一系列脑肿瘤的共同特征。特别是,在24例高级别星形细胞瘤(恶性星形细胞瘤和多形性胶质母细胞瘤)中有18例发现ras p21表达升高,相比之下,9例低级别(高分化星形细胞瘤)中有3例出现该情况(P小于0.05)。这些结果表明,ras p21表达可能是恶性星形细胞瘤和多形性胶质母细胞瘤的一个重要分子标志物。